MedTrace Logo

Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

NCT02033018 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-01-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary

Conditions

  • Choroidal Retinal Neovascularization

Interventions

DRUG

Aflibercept Injection

Aflibercept intravitreal injection

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Principal Investigators

  • Joao J Nassaralla, Jr · Instituto de Olhos de Goiânia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033018 on ClinicalTrials.gov